South Georgia Capital’s Teva Pharmaceuticals TEVA Stock Holding History

South Georgia Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-200	Closed	-$12K	–	204
2015 Q1	$12K	Hold	200	–	–	0.02%	146
2014 Q4	$12K	Hold	200	–	–	0.02%	136
2014 Q3	$11K	Hold	200	–	–	0.02%	145
2014 Q2	$10K	Hold	200	–	–	0.01%	153
2014 Q1	$11K	Hold	200	–	–	0.01%	143
2013 Q4	$8K	Buy	+200	New	+$7.88K	0.01%	181

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

South Georgia Capital's TEVA Position: Q2 2015 in Review

South Georgia Capital sold out of Teva Pharmaceuticals (TEVA) in Q2 2015, closing a stake of 200 shares — an estimated $12K sold.

South Georgia Capital first reported a position in TEVA in Q4 2013 and held it in 6 quarters. The position peaked at $12K in Q1 2015. 818 funds tracked by Wall St. Rank hold TEVA as of Q2 2015.

South Georgia Capital reported no remaining Teva Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
South Georgia Capital sold 200 Teva Pharmaceuticals shares in Q2 2015, an estimated $12K.
South Georgia Capital first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 6 quarters.
South Georgia Capital's Teva Pharmaceuticals position peaked at $12K in Q1 2015.
818 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2015.

Based on South Georgia Capital's 13F filing for Q2 2015, filed 11 Aug 2015.